Related Experiment Video
Updated: Apr 30, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Abiraterone acetate (AA): current guidelines of prescription of abiraterone]
Emilie Boissier1, Yohann Loriot2, Stéphane Vignot3
1Institut Gustave-Roussy, DITEP, Département d'innovations thérapeutiques et essais précoces, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France.
Abstract:
Abiraterone acetate (AA) is a selective inhibitor of cytochrom p450 (CYP)17 which is required for androgen biosynthesis, and can block the androgens synthesis by testicles, surrenals and intratumoral secretion. In phase I and II studies in patients with prostate cancer, therapy with AA 250-2000 mg once daily demonstrated reductions in prostate specific antigen (PSA), and/or circulating tumor cells (CTCs). In two large phase III trials in patients with metastatic castration resistant prostate cancer (CRPC) in post-docetaxel and pre-docetaxel setting, AA plus prednisone compared with placebo plus prednisone demonstrated a significant superior overall survival in post-docetaxel setting, and a superior radiological PFS in pre-docetaxel setting. Based of these results, AA is approved in metastatic CRPC patients in post-docetaxel setting or pre-docetaxel setting in 2013.
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

